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Background: Whereas reperfusion injury accounts for up to 50% of the injury of ischemia/reperfusion (I/R), no therapies are available targeting 
this. Histone deacetylases (HDAC) inhibitor reduces infarct size by 50% in mouse I/R models. Translating these results to human, however, requires 
large animal testing and underlying mechanisms remain undefined. Here, we hypothesize that SAHA, an HDAC inhibitor which is FDA-approved for 
cancer, will a) blunt I/R injury by b) targeting reperfusion injury and c) through autophagy.
methods: Twenty-one rabbits were randomized into 3 groups: a) DMSO control, b) SAHA pretreatment (one day before and at surgery), and c) SAHA 
reperfusion-only (at reperfusion) and subjected to I/R (30 min, 24h). This latter arm mimics the clinical situation where patients undergo PCI for 
STEMI. Western blots, electron microscopy (EM) and fluorescence imaging were used to detect autophagy.
results: SAHA reduced infarct size normalized to area at risk and partially rescued systolic function when given before surgery or only at 
reperfusion. Measured rabbit SAHA plasma concentration is achievable in human. In the infarct border zone, SAHA increased autophagy as 
measured by LC3II levels, a finding verified by EM. In mice expressing RFP-GFP-LC3 and subjected to I/R, SAHA increased autophagic flux at the 
border zone measured as LC3 and lysosome puncta. In cultured neonatal rat ventricular cardiomyocytes (NRVM) subjected to simulated I/R, 
SAHA treatment increased basal autophagic flux and maintained it during both ischemia and reperfusion. In contrast, DMSO-treated NRVMs had 
decreases in autophagy during I/R. SAHA-induced autophagic flux was corroborated by increased LC3 and lyososome puncta in NRVMs infected 
with adenovirus GFP-LC3 and lysotracker treatment. In NRVM, treatment with SAHA reduced I/R-induced cell death by around 40%. Removal of an 
essential autophagy protein, ATG7 abolished SAHA’s cardiomyocyte protective effect.
conclusion: Translationally, FDA-approved HDAC inhibitor, SAHA, reduces infarct size in a large animal model. Mechanistically, the cardioprotective 
effects of SAHA during I/R likely occur through normalizing autophagic flux.
